Protagenic Therapeutics, Inc.\new
Close on Oct 19, 2026
- Market cap
- $1.36M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Protagenic Therapeutics, Inc.\new has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Protagenic Therapeutics, Inc.\new filed with the SEC
Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Listing notice · Auditor change · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance
Listing notice · Auditor change · Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Receives $3.1 Million from Recent Warrant Activity
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Therapeutics to Effect 1-for-14 Reverse Stock Split
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics’ Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Resolution of Nasdaq Deficiency Notice
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Therapeutics to Effect 1-for-4 Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K